ClinicalTrials.gg
CompletedNCT01986881Updated Sep 23, 2022Results posted

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

A Phase 3 interventional study of Ertugliflozin and Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-09-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,246
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
Largest of 28
8,246 · median 83
Started
2013
with 5 others
Phase 3
11 of 28
none open now
Registered
9th of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

An overall study of the cardiovascular outcomes following treatment with ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and established vascular disease. The main objective of this study is to assess the cardiovascular safety of ertugliflozin. This trial includes 3 pre-defined glycemic sub-studies; 1. In participants receiving background insulin with or without metformin, 2. In participants receiving background sulfonylurea monotherapy, and 3. In participants receiving background metformin with sulfonylurea (all fully-enrolled).

Participants enrolled prior to Amendment 1 were in the overall study as well as a sub-study, if they met certain entry criteria. Participants enrolled following the start of Amendment 1 were only enrolled in the overall study. The sub-studies were the initial 18 weeks of the overall study period.

Read the detailed description

The primary hypotheses for the 4 studies are:

  1. Overall Cardiovascular Study:

    The time to first occurrence of the composite endpoint of MACE: cardiovascular death, non-fatal myocardial infarction [MI] or non-fatal stroke in participants treated with ertugliflozin is non-inferior compared to that in participants treated with placebo.

  2. The 3 Glycemic Sub-studies:

    1. The mean reduction from baseline in hemoglobin A1c (A1C) for 15 mg ertugliflozin is greater than that for placebo.
    2. The mean reduction from baseline in A1C for 5 mg ertugliflozin is greater than that for placebo.
03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of T2DM in accordance with American Diabetes Association (ADA) guidelines
  • (A1C) at the start of study participation of 7.0-10.5% (53-91 mmol/mol)
  • On stable allowable anti-hyperglycemic agents (AHA) or on no background AHA for at least 8 weeks prior to the study participation
  • (BMI) > or = to 18.0 kg/m\^2
  • Evidence or a history of atherosclerosis involving the coronary, cerebral or peripheral vascular systems
  • There is adequate documentation of the objective evidence that the participant has established vascular disease such as site's medical records, copies of such records from other institutions, or a letter from a referring physician that specifically states the diagnosis and date of the most recent occurrence of the qualifying event(s) or procedure(s).
  • Male, female not or , or female of reproductive potential who agrees to be abstinent from heterosexual activity or agrees to use or have their partner use 2 acceptable methods of

Exclusion criteria

Exclusion Criteria (Overall Cardiovascular Study):

  • Previous randomization into this trial
  • Experiencing a cardiovascular event (myocardial infarction or stroke) or undergoing coronary angioplasty or peripheral intervention procedure between the Screening Visit and randomization
  • Undergoing any cardiovascular surgery (valvular surgery) within 3 months of study participation
  • Planned revascularization or peripheral intervention procedure or other cardiovascular surgery
  • (NYHA) IV heart failure at study participation
  • History of type 1 diabetes mellitus or a history of ketoacidosis

Key Inclusion Criteria for the 3 Glycemic Sub-studies:

  1. Insulin With or Without Metformin Sub-study: Stable doses of insulin (>=20 units/day, with variations up to 10% in the daily dose permitted) with or without metformin (>=1500 mg/day) for at least 8 weeks prior to the time of the Screening Visit (V1) and during the period between the Screening Visit (V1) and randomization.
  2. Sulfonylurea (SU) Monotherapy Sub-study: Participants receiving a stable dose of SU monotherapy for at least 8 weeks prior to the time of the Screening Visit (V1) and during the period between the Screening Visit (V1) and randomization.
  3. Metformin with SU Sub-study: Participants receiving a stable dose metformin (≥1500 mg/day) with a SU for at least 8 weeks prior to the time of the Screening Visit (V1) and during the period between the Screening Visit (V1) and randomization.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
8,246 participants (actual)

Study arms

  • Experimental
    Ertugliflozin, 15 mg

    Ertugliflozin 15 mg administered orally once daily for up to approximately 6 years

    Drug: Ertugliflozin · Drug: Glycemic Rescue

  • Experimental
    Ertugliflozin, 5 mg

    Ertugliflozin 5 mg administered orally once daily for up to approximately 6 years

    Drug: Ertugliflozin · Drug: Placebo · Drug: Glycemic Rescue

  • Placebo comparator
    Placebo

    Matching placebo to ertugliflozin administered orally once daily for up to approximately 6 years

    Drug: Placebo · Drug: Glycemic Rescue

Interventions

  • Oral, once daily, for up to approximately 6 years

    Also known as: MK-8835, PF-04971729, Steglatro

  • DrugPlacebo

    Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years

  • DrugGlycemic Rescue

    Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea \[SU\], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study)

    Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke. The on-treatment approach included confirmed events that occurred between the date of first dose of study medication and the on-treatment censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or 365 days after the last dose).

    Time frame: Up to approximately 6 years

  2. Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.

    Time frame: Baseline

  3. Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  4. Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.

    Time frame: Baseline

  5. Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  6. Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects Week 0 A1C.

    Time frame: Baseline

  7. Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

Secondary outcomes

  1. Time to Occurrence of Cardiovascular (CV) Death or Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)

    Time to the occurrence of any of the following adjudicated components of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)) or hospitalization for heart failure. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).

    Time frame: Up to approximately 6 years

  2. Time to Occurrence of Cardiovascular Death (On-study Approach) (Overall Cardiovascular Study)

    Time to the occurrence of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to CV death or time to censoring (the earliest of participants' end of study date or date last known to be alive).

    Time frame: Up to approximately 6 years

  3. Time to First Occurrence of the Renal Composite: the Composite of Renal Death, Renal Dialysis/Transplant, or Doubling of Serum Creatinine From Baseline (On-Study Approach) (Overall Cardiovascular Study)

    Renal composite endpoint was defined as a composite of renal death, renal dialysis/transplant, or doubling of serum creatinine from baseline. The on-study approach included events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.

    Time frame: Up to approximately 6 years

  4. Time to First Occurrence of MACE Plus (Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke or Hospitalization for Unstable Angina) (On-Study Approach) (Overall Cardiovascular Study)

    Time to the first occurrence of any of the following adjudicated components 4-point MACE: cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina pectoris. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.

    Time frame: Up to approximately 6 years

  5. Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction (On-Study Approach) (Overall Cardiovascular Study)

    Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).

    Time frame: Up to approximately 6 years

  6. Time to First Occurrence of Fatal or Non-fatal Stroke (FNF Stroke) (On-Study Approach) (Overall Cardiovascular Study)

    Time to the first occurrence of fatal and no-fatal stroke. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.

    Time frame: Up to approximately 6 years

  7. Time to First Occurrence of Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)

    Time to the first occurrence of heart failure requiring hospitalization (adjudicated). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.

    Time frame: Up to approximately 6 years

  8. Time to Occurrence of Death From Any Cause (On-Study Approach) (Overall Cardiovascular Study)

    Time to the occurrence of death from any cause. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or date last known to be alive. The on-study approach included events that occurred between the randomization date and the on-study censor date.

    Time frame: Up to approximately 6 years

  9. Andersen-Gill Model for Total MACE (On-Study Approach) (Overall Cardiovascular Study)

    All events (first and recurrent) of the composite of MACE (3-point major adverse cardiovascular events: cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke) were assessed using Andersen-Gill model. The on-study approach included events that occurred between the randomization date and the on-study censor date.

    Time frame: Up to approximately 6 years

  10. Andersen-Gill Model for All Cardiovascular Death (CV Death) or Hospitalizations for Heart Failure (HFF) (On-Study Approach) (Overall Cardiovascular Study)

    All events (first and recurrent) of the composite of CV death and HHF were assessed using an Andersen-Gill model. Person-years were calculated as the sum of time from randomization to end of follow-up. The on-study approach included events that occurred between the randomization date and the on-study censor date.

    Time frame: Up to approximately 6 years

  11. Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  12. Change From Baseline in A1C at Week 52 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Week 52

  13. Change From Baseline in A1C at Month 24 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 24 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 24

  14. Change From Baseline in A1C at Month 36 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 36 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 36

  15. Change From Baseline in A1C at Month 48 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 48 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 48

  16. Change From Baseline in A1C at Month 60 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 60 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 60

  17. Change From Baseline in A1C at Month 72 (Overall Cardiovascular Study)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 72 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 72

  18. Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Week 18

  19. Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 52 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Week 52

  20. Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 24 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Month 24

  21. Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 36 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Month 36

  22. Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 48 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Month 48

  23. Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 60 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Month 60

  24. Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 18 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Week 18

  25. Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 52 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Week 52

  26. Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 24 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Month 24

  27. Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 36 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Month 36

  28. Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 48 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Month 48

  29. Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 60 (Overall Cardiovascular Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Month 60

  30. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)

    FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  31. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 (Overall Cardiovascular Study)

    FPG was analyzed after an overnight fast. This change from baseline reflects the Week 52 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Week 52

  32. Change From Baseline in Fasting Plasma Glucose (FPG) at Month 24 (Overall Cardiovascular Study)

    FPG was analyzed after an overnight fast. This change from baseline reflects the Month 24 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 24

  33. Change From Baseline in Fasting Plasma Glucose (FPG) at Month 36 (Overall Cardiovascular Study)

    FPG was analyzed after an overnight fast. This change from baseline reflects the Month 36 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 36

  34. Change From Baseline in Fasting Plasma Glucose (FPG) at Month 48 (Overall Cardiovascular Study)

    FPG was analyzed after an overnight fast. This change from baseline reflects the Month 48 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 48

  35. Change From Baseline in Fasting Plasma Glucose (FPG) at Month 60 (Overall Cardiovascular Study)

    FPG was analyzed after an overnight fast. This change from baseline reflects the Month 60 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 60

  36. Change From Baseline in Fasting Plasma Glucose (FPG) at Month 72 (Overall Cardiovascular Study)

    FPG was analyzed after an overnight fast. This change from baseline reflects the Month 72 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 72

  37. Time to the First Occurrence of a Participant Receiving Glycemic Rescue Therapy Through Week 18 (Overall Cardiovascular Study)

    Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.

    Time frame: Up to 18 weeks

  38. Time to Initiation of Insulin for Participants Not on Insulin at Baseline (Overall Cardiovascular Study)

    Participants who were not on insulin therapy at the start of study medication.

    Time frame: Up to approximately 6 years

  39. Baseline Insulin Dose for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

    Baseline reflects Week 0 insulin dose.

    Time frame: Baseline

  40. Change From Baseline in Insulin Dose at Week 18 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

    This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

    Time frame: Baseline and Week 18

  41. Change From Baseline in Insulin Dose at Week 52 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

    This change from baseline reflects the Week 52 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

    Time frame: Baseline and Week 52

  42. Change From Baseline in Insulin Dose at Month 24 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

    This change from baseline reflects the Month 24 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

    Time frame: Baseline and Month 24

  43. Change From Baseline in Insulin Dose at Month 36 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

    This change from baseline reflects the Month 36 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

    Time frame: Baseline and Month 36

  44. Change From Baseline in Insulin Dose at Month 48 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

    This change from baseline reflects the Month 48 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

    Time frame: Baseline and Month 48

  45. Change From Baseline in Insulin Dose at Month 60 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

    This change from baseline reflects the Month 60 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

    Time frame: Baseline and Month 60

  46. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)

    This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  47. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 (Overall Cardiovascular Study)

    This change from baseline reflects the Week 52 sitting SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Week 52

  48. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 24 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 24 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 24

  49. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 36 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 36 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 36

  50. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 48 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 48 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 48

  51. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 60 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 60 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 60

  52. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 72 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 72 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 72

  53. Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)

    This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  54. Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 52 (Overall Cardiovascular Study)

    This change from baseline reflects the Week 52 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Week 52

  55. Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 24 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 24 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 24

  56. Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 36 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 36 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 36

  57. Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 48 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 48 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 48

  58. Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 60 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 60 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 60

  59. Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 72 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 72 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 72

  60. Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)

    This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  61. Change From Baseline in Body Weight at Week 52 (Overall Cardiovascular Study)

    This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Week 52

  62. Change From Baseline in Body Weight at Month 24 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 24 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 24

  63. Change From Baseline in Body Weight at Month 36 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 36 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 36

  64. Change From Baseline in Body Weight at Month 48 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 48 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 48

  65. Change From Baseline in Body Weight at Month 60 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 60 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 60

  66. Change From Baseline in Body Weight at Month 72 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 72 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 72

  67. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 18 (Overall Cardiovascular Study)

    This change from baseline reflects the Week 18 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.

    Time frame: Baseline and Week 18

  68. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52 (Overall Cardiovascular Study)

    This change from baseline reflects the Week 52 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.

    Time frame: Baseline and Week 52

  69. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 24 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 24 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.

    Time frame: Baseline and Month 24

  70. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 36 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 36 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.

    Time frame: Baseline and Month 36

  71. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 48 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 48 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.

    Time frame: Baseline and Month 48

  72. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 60 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 60 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.

    Time frame: Baseline and Month 60

  73. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 72 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 72 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.

    Time frame: Baseline and Month 72

  74. Baseline Serum Creatinine (Overall Cardiovascular Study)

    Baseline reflects Week 0 serum creatinine.

    Time frame: Baseline

  75. Change From Baseline in Serum Creatinine at Week 18 (Overall Cardiovascular Study)

    This change from baseline reflects the Week 18 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Week 18

  76. Change From Baseline in Serum Creatinine at Week 52 (Overall Cardiovascular Study)

    This change from baseline reflects the Week 52 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Week 52

  77. Change From Baseline in Serum Creatinine at Month 24 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 24 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 24

  78. Change From Baseline in Serum Creatinine at Month 36 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 36 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 36

  79. Change From Baseline in Serum Creatinine at Month 48 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 48 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 48

  80. Change From Baseline in Serum Creatinine at Month 60 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 60 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 60

  81. Change From Baseline in Serum Creatinine at Month 72 (Overall Cardiovascular Study)

    This change from baseline reflects the Month 72 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 72

  82. Baseline Urinary Albumin/Creatinine Ratio (Overall Cardiovascular Study)

    Baseline reflects Week 0 albumin/creatinine ratio.

    Time frame: Baseline

  83. Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 18 (Overall Cardiovascular Study)

    This percent change relative to baseline reflects the Week 18 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Week 18

  84. Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 52 (Overall Cardiovascular Study)

    This percent change relative to baseline reflects the Week 52 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Week 52

  85. Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 24 (Overall Cardiovascular Study)

    This percent change relative to baseline reflects the Month 24 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 24

  86. Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 36 (Overall Cardiovascular Study)

    This percent change relative to baseline reflects the Month 36 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 36

  87. Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 48 (Overall Cardiovascular Study)

    This percent change relative to baseline reflects the Month 48 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 48

  88. Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 60 (Overall Cardiovascular Study)

    This percent change relative to baseline reflects the Month 60 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

    Time frame: Baseline and Month 60

  89. Percentage of Participants With Albuminuria Progression or Regression at Week 18 (Overall Cardiovascular Study)

    Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal-albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

    Time frame: Week 18

  90. Percentage of Participants With Albuminuria Progression or Regression at Week 52 (Overall Cardiovascular Study)

    Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

    Time frame: Week 52

  91. Percentage of Participants With Albuminuria Progression or Regression at Month 24 (Overall Cardiovascular Study)

    Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

    Time frame: Month 24

  92. Percentage of Participants With Albuminuria Progression or Regression at Month 36 (Overall Cardiovascular Study)

    Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

    Time frame: Month 36

  93. Percentage of Participants With Albuminuria Progression or Regression at Month 48 (Overall Cardiovascular Study)

    Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline and normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

    Time frame: Month 48

  94. Percentage of Participants With Albuminuria Progression or Regression at Month 60 (Overall Cardiovascular Study)

    Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

    Time frame: Month 60

  95. Percentage of Participants Experiencing an Adverse Event (AE) (Overall Cardiovascular Study)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to approximately 6 years

  96. Percentage of Participants Experiencing an Adverse Event (AE) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 18 weeks

  97. Percentage of Participants Experiencing an Adverse Event (AE) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 18 weeks

  98. Percentage of Participants Experiencing an Adverse Event (AE) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 18 weeks

  99. Percentage of Participants Discontinuing Study Treatment Due to An AE (Overall Cardiovascular Study)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to approximately 6 years

  100. Percentage of Participants Discontinuing Study Treatment Due to An AE (Insulin With or Without Metformin Add-on Glycemic Sub-study)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 18 weeks

  101. Percentage of Participants Discontinuing Study Treatment Due to An AE (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 18 weeks

  102. Percentage of Participants Discontinuing Study Treatment Due to An AE (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 18 weeks

  103. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

    FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in the FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  104. Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

    This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  105. Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Week 18

  106. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

    This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  107. Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

    This change from baseline reflects the Week 18 DBP minus the Week 0 BBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  108. Baseline Insulin Dose for Participants Receiving Insulin at Baseline - (Insulin With or Without Metformin Add-on Glycemic Sub-study)

    Baseline reflects Week 0 insulin dose.

    Time frame: Baseline

  109. Change From Baseline at Week 18 in Insulin Dose for Participants Receiving Insulin at Baseline - Including Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)

    This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a decrease in insulin dose. Participants who met glycemic rescue criteria received glycemic rescue medication. "Including rescue", included data following the initiation of rescue therapy.

    Time frame: Baseline and Week 18

  110. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

    FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  111. Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

    This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  112. Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Week 18

  113. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

    This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  114. Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

    This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  115. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

    FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  116. Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

    This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  117. Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Week 18

  118. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

    This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

  119. Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

    This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 18

07

Results

Posted Feb 15, 2021

Participant flow

This study included participants in 34 countries at 548 study centers (Overall Cardiovascular Study).

Participant flow — Overall Study
MilestoneErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Started275227472747
Treated274627472745
Participants enrolled in the insulin +/- metformin glycemic sub-study348370347
Participants enrolled in the sulfonylurea monotherapy glycemic sub-study555448
Participants enrolled in the metformin with sulfonylurea glycemic sub-study100113117
Completed242224012389
Not completed330346358
Withdrew: Death228233247
Withdrew: Lost to follow-up514455
Withdrew: Physician decision746
Withdrew: Study site terminated by sponsor223
Withdrew: Withdrawal by subject416045
Withdrew: Subject moved010
Withdrew: Other122

Outcome measures

PrimaryTime to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study)

Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke. The on-treatment approach included confirmed events that occurred between the date of first dose of study medication and the on-treatment censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or 365 days after the last dose).

Time frame:
Up to approximately 6 years
Reported as:
Number · Events per 100 Person-years
Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study)
Events per 100 Person-yearsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study)3.644.164.013.90
Statistical analysis
  • Placebo (Overall Cardiovascular Study) vs All Ertugliflozin (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = <0.001 (Model included treatment as an explanatory factor and cohort category as a stratification factor.) · Hazard ratio (hr): 0.97 · 95.6% CI 0.848 to 1.114
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.002 · Hazard ratio (hr): 1.04 · 95.6% CI 0.887 to 1.211Model included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = <0.001 · Hazard ratio (hr): 0.91 · 95.6% CI 0.773 to 1.065Model included treatment as an explanatory factor and cohort category as a stratification factor.
PrimaryBaseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.

Time frame:
Baseline
Reported as:
Mean · A1C Percentage
Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
A1C PercentageErtugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Ins+/-Met Sub-study)
Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study)8.45 ± 0.9448.38 ± 0.9858.39 ± 0.928
PrimaryChange From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · A1C Percentage
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)
A1C PercentageErtugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Ins+/-Met Sub-study)
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)-0.77 (-0.86 to -0.67)-0.84 (-0.93 to -0.74)-0.19 (-0.29 to -0.09)
Statistical analysis
  • Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Ins+/-Met Sub-study) · cLDA Model · p = <0.001 (Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, stratum, and the interaction of time by treatment. The stratum was (insulin alone or insulin+metformin) and "Time" was a categorical variable.) · Difference in the least squares means: -0.65 · 95% CI -0.78 to -0.51
  • Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Ins+/-Met Sub-study) · Constrained longitudinal data analysis · p = <0.001 (Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, stratum, and the interaction of time by treatment. The stratum was (insulin alone or insulin+metformin) and "Time" was a categorical variable.) · Difference in the least squares means: -0.58 · 95% CI -0.71 to -0.44
PrimaryBaseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.

Time frame:
Baseline
Reported as:
Mean · A1C Percentage
Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
A1C PercentageErtugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study)
Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)8.27 ± 0.9998.39 ± 1.0198.21 ± 1.169
PrimaryChange From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · A1C Percentage
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
A1C PercentageErtugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study)
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)-0.91 (-1.17 to -0.65)-0.78 (-1.06 to -0.51)-0.56 (-0.84 to -0.27)
Statistical analysis
  • Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study) · cLDA Model · p = 0.247 (Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, and the interaction of time by treatment.) · Difference in the least squares means: -0.22 · 95% CI -0.60 to 0.16
  • Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study) · cLDA model · p = 0.063 (Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, and the interaction of time by treatment.) · Difference in the least squares means: -0.35 · 95% CI -0.72 to 0.02
PrimaryBaseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects Week 0 A1C.

Time frame:
Baseline
Reported as:
Mean · A1C Percentage
Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
A1C PercentageErtugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)Placebo (Metformin With Sulfonylurea Glycemic Sub-study)
Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)8.39 ± 0.9608.30 ± 0.9638.27 ± 0.994
PrimaryChange From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · A1C Percentage
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
A1C PercentageErtugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)Placebo (Metformin With Sulfonylurea Glycemic Sub-study)
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study)-0.89 (-1.06 to -0.71)-0.98 (-1.14 to -0.82)-0.23 (-0.39 to -0.06)
Statistical analysis
  • Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · cLDA Model · p = <0.001 (Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, and the interaction of time by treatment.) · Difference in the least squares means: -0.75 · 95% CI -0.98 to -0.53
  • Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · cLDA model · p = <0.001 (Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, and the interaction of time by treatment.) · Difference in the least squares means: -0.66 · 95% CI -0.89 to -0.43
SecondaryTime to Occurrence of Cardiovascular (CV) Death or Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)

Time to the occurrence of any of the following adjudicated components of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)) or hospitalization for heart failure. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).

Time frame:
Up to approximately 6 years
Reported as:
Number · Events per 100 Person-years
Time to Occurrence of Cardiovascular (CV) Death or Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)
Events per 100 Person-yearsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Time to Occurrence of Cardiovascular (CV) Death or Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)2.362.332.662.34
Statistical analysis
  • Placebo (Overall Cardiovascular Study) vs All Ertugliflozin (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.108 · Hazard ratio (hr): 0.88 · 95.8% CI 0.750 to 1.034Model included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.150 · Hazard ratio (hr): 0.88 · 95.8% CI 0.725 to 1.057Model included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.188 · Hazard ratio (hr): 0.89 · 95.8% CI 0.735 to 1.068Model included treatment as an explanatory factor and cohort category as a stratification factor.
SecondaryTime to Occurrence of Cardiovascular Death (On-study Approach) (Overall Cardiovascular Study)

Time to the occurrence of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to CV death or time to censoring (the earliest of participants' end of study date or date last known to be alive).

Time frame:
Up to approximately 6 years
Reported as:
Number · Events per 100 Person-years
Time to Occurrence of Cardiovascular Death (On-study Approach) (Overall Cardiovascular Study)
Events per 100 Person-yearsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Time to Occurrence of Cardiovascular Death (On-study Approach) (Overall Cardiovascular Study)1.771.741.901.76
Statistical analysis
  • Placebo (Overall Cardiovascular Study) vs All Ertugliflozin (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.385 · Hazard ratio (hr): 0.92 · 95.8% CI 0.767 to 1.113Model included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.417 · Hazard ratio (hr): 0.92 · 95.8% CI 0.739 to 1.139Model included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.494 · Hazard ratio (hr): 0.93 · 95.8% CI 0.750 to 1.154Model included treatment as an explanatory factor and cohort category as a stratification factor.
SecondaryTime to First Occurrence of the Renal Composite: the Composite of Renal Death, Renal Dialysis/Transplant, or Doubling of Serum Creatinine From Baseline (On-Study Approach) (Overall Cardiovascular Study)

Renal composite endpoint was defined as a composite of renal death, renal dialysis/transplant, or doubling of serum creatinine from baseline. The on-study approach included events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.

Time frame:
Up to approximately 6 years
Reported as:
Number · Events per 100 Person-years
Time to First Occurrence of the Renal Composite: the Composite of Renal Death, Renal Dialysis/Transplant, or Doubling of Serum Creatinine From Baseline (On-Study Approach) (Overall Cardiovascular Study)
Events per 100 Person-yearsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Time to First Occurrence of the Renal Composite: the Composite of Renal Death, Renal Dialysis/Transplant, or Doubling of Serum Creatinine From Baseline (On-Study Approach) (Overall Cardiovascular Study)0.870.981.150.93
Statistical analysis
  • Placebo (Overall Cardiovascular Study) vs All Ertugliflozin (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.081 · Hazard ratio (hr): 0.81 · 95.8% CI 0.630 to 1.036Model included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazard Model · p = 0.258 · Hazard ratio (hr): 0.85 · 95.8% CI 0.638 to 1.137Model included treatment as an explanatory factor and cohort category as a stratification factor. Renal
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.065 · Hazard ratio (hr): 0.76 · 95.8% CI 0.568 to 1.028Model included treatment as an explanatory factor and cohort category as a stratification factor.
SecondaryTime to First Occurrence of MACE Plus (Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke or Hospitalization for Unstable Angina) (On-Study Approach) (Overall Cardiovascular Study)

Time to the first occurrence of any of the following adjudicated components 4-point MACE: cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina pectoris. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.

Time frame:
Up to approximately 6 years
Reported as:
Number · Events per 100 Person-years
Time to First Occurrence of MACE Plus (Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke or Hospitalization for Unstable Angina) (On-Study Approach) (Overall Cardiovascular Study)
Events per 100 Person-yearsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Time to First Occurrence of MACE Plus (Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke or Hospitalization for Unstable Angina) (On-Study Approach) (Overall Cardiovascular Study)4.424.674.924.54
Statistical analysis
  • Placebo (Overall Cardiovascular Study) vs All Ertugliflozin (Overall Cardiovascular Study) · Cox proportional hazards model · p = 0.183 (Hazard ratio, CI, and 2-sided p-value comparing All Ertugliflozin versus Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.) · Hazard ratio (hr): 0.92 · 95% CI 0.823 to 1.038
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.450 · Hazard ratio (hr): 0.95 · 95% CI 0.831 to 1.086Model included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.123 · Hazard ratio (hr): 0.90 · 95% CI 0.785 to 1.029Model included treatment as an explanatory factor and cohort category as a stratification factor.
SecondaryTime to First Occurrence of Fatal or Non-fatal Myocardial Infarction (On-Study Approach) (Overall Cardiovascular Study)

Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).

Time frame:
Up to approximately 6 years
Reported as:
Number · Events per 100 Person-years
Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction (On-Study Approach) (Overall Cardiovascular Study)
Events per 100 Person-yearsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction (On-Study Approach) (Overall Cardiovascular Study)1.552.001.701.77
Statistical analysis
  • Placebo (Overall Cardiovascular Study) vs All Ertugliflozin (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.676 · Hazard ratio (hr): 1.04 · 95% CI 0.861 to 1.259Model included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.139 · Hazard ratio (hr): 1.17 · 95% CI 0.949 to 1.451Model included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.416 · Hazard ratio (hr): 0.91 · 95% CI 0.727 to 1.141Model included treatment as an explanatory factor and cohort category as a stratification factor.
SecondaryTime to First Occurrence of Fatal or Non-fatal Stroke (FNF Stroke) (On-Study Approach) (Overall Cardiovascular Study)

Time to the first occurrence of fatal and no-fatal stroke. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.

Time frame:
Up to approximately 6 years
Reported as:
Number · Events per 100 Person-years
Time to First Occurrence of Fatal or Non-fatal Stroke (FNF Stroke) (On-Study Approach) (Overall Cardiovascular Study)
Events per 100 Person-yearsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Time to First Occurrence of Fatal or Non-fatal Stroke (FNF Stroke) (On-Study Approach) (Overall Cardiovascular Study)0.921.040.930.98
Statistical analysis
  • Placebo (Overall Cardiovascular Study) vs All Ertugliflozin (Overall Cardiovascular Study) · Cox proportional hazards model · p = 0.663 (Hazard ratio, CI, and 2-sided p-value comparing All Ertugliflozin versus Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.) · Hazard ratio (hr): 1.06 · 95% CI 0.820 to 1.365Hazard ratio, CI, and 2-sided p-value comparing All Ertugliflozin versus Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox proportional hazards model · p = 0.415 (A two-sided p-value compared Ertugliflozin vs Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.) · Hazard ratio (hr): 1.13 · 95% CI 0.845 to 1.505
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox proportional hazards model · p = 0.953 (A two-sided p-value compared Ertugliflozin vs Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.) · Hazard ratio (hr): 0.99 · 95% CI 0.736 to 1.334
SecondaryTime to First Occurrence of Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)

Time to the first occurrence of heart failure requiring hospitalization (adjudicated). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.

Time frame:
Up to approximately 6 years
Reported as:
Number · Events per 100 Person-years
Time to First Occurrence of Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)
Events per 100 Person-yearsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Time to First Occurrence of Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)0.750.721.050.73
Statistical analysis
  • Placebo (Overall Cardiovascular Study) vs All Ertugliflozin (Overall Cardiovascular Study) · Cox proportional hazards model · p = 0.006 (Hazard ratio, CI, and 2-sided p-value comparing All Ertugliflozin versus Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.) · Hazard ratio (hr): 0.70 · 95% CI 0.539 to 0.902
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.016 · Hazard ratio (hr): 0.68 · 95% CI 0.502 to 0.932Hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.028 · Hazard ratio (hr): 0.71 · 95% CI 0.524 to 0.964Hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.
SecondaryTime to Occurrence of Death From Any Cause (On-Study Approach) (Overall Cardiovascular Study)

Time to the occurrence of death from any cause. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or date last known to be alive. The on-study approach included events that occurred between the randomization date and the on-study censor date.

Time frame:
Up to approximately 6 years
Reported as:
Number · Events per 100 Person-years
Time to Occurrence of Death From Any Cause (On-Study Approach) (Overall Cardiovascular Study)
Events per 100 Person-yearsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Time to Occurrence of Death From Any Cause (On-Study Approach) (Overall Cardiovascular Study)2.422.462.622.44
Statistical analysis
  • Placebo (Overall Cardiovascular Study) vs All Ertugliflozin (Overall Cardiovascular Study) · Cox proportional hazards model · p = 0.340 (Hazard ratio, CI, and 2-sided p-value comparing Ertugliflozin vs Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.) · Hazard ratio (hr): 0.93 · 95% CI 0.797 to 1.081
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.463 · Hazard ratio (hr): 0.94 · 95% CI 0.784 to 1.117Model included treatment as an explanatory factor and cohort category as a stratification factor.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Cox Proportional Hazards Model · p = 0.363 · Hazard ratio (hr): 0.92 · 95% CI 0.771 to 1.100Model included treatment as an explanatory factor and cohort category as a stratification factor.
SecondaryAndersen-Gill Model for Total MACE (On-Study Approach) (Overall Cardiovascular Study)

All events (first and recurrent) of the composite of MACE (3-point major adverse cardiovascular events: cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke) were assessed using Andersen-Gill model. The on-study approach included events that occurred between the randomization date and the on-study censor date.

Time frame:
Up to approximately 6 years
Reported as:
Number · Events per 100 Person-years
Andersen-Gill Model for Total MACE (On-Study Approach) (Overall Cardiovascular Study)
Events per 100 Person-yearsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Andersen-Gill Model for Total MACE (On-Study Approach) (Overall Cardiovascular Study)4.354.914.594.63
Statistical analysis
  • Placebo (Overall Cardiovascular Study) vs All Ertugliflozin (Overall Cardiovascular Study) · Hazard ratio (hr): 1.01 · 95% CI 0.898 to 1.131
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Hazard ratio (hr): 1.07 · 95% CI 0.937 to 1.219
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Hazard ratio (hr): 0.95 · 95% CI 0.828 to 1.085
SecondaryAndersen-Gill Model for All Cardiovascular Death (CV Death) or Hospitalizations for Heart Failure (HFF) (On-Study Approach) (Overall Cardiovascular Study)

All events (first and recurrent) of the composite of CV death and HHF were assessed using an Andersen-Gill model. Person-years were calculated as the sum of time from randomization to end of follow-up. The on-study approach included events that occurred between the randomization date and the on-study censor date.

Time frame:
Up to approximately 6 years
Reported as:
Number · Events per 100 Person-years
Andersen-Gill Model for All Cardiovascular Death (CV Death) or Hospitalizations for Heart Failure (HFF) (On-Study Approach) (Overall Cardiovascular Study)
Events per 100 Person-yearsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Andersen-Gill Model for All Cardiovascular Death (CV Death) or Hospitalizations for Heart Failure (HFF) (On-Study Approach) (Overall Cardiovascular Study)2.922.713.422.82
Statistical analysis
  • Placebo (Overall Cardiovascular Study) vs All Ertugliflozin (Overall Cardiovascular Study) · Hazard ratio (hr): 0.82 · 95% CI 0.716 to 0.945
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Hazard ratio (hr): 0.79 · 95% CI 0.673 to 0.935Ertugliflozin vs Placebo, based on the Andersen-Gill model for the recurrent events at the end of study.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Hazard ratio (hr): 0.85 · 95% CI 0.725 to 1.001Ertugliflozin vs Placebo, based on the Andersen-Gill model for the recurrent events at the end of study.
SecondaryChange From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · A1C Percentage
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Overall Cardiovascular Study)
A1C PercentageErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Overall Cardiovascular Study)-0.70 (-0.73 to -0.67)-0.72 (-0.75 to -0.69)-0.22 (-0.25 to -0.19)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA Model · p = <0.001 · Difference in the least squares means: -0.50 · 95% CI -0.55 to -0.46cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA model · p = <0.001 · Difference in the least squares means: -0.48 · 95% CI -0.53 to -0.44cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in A1C at Week 52 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · A1C Percentage
Change From Baseline in A1C at Week 52 (Overall Cardiovascular Study)
A1C PercentageErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in A1C at Week 52 (Overall Cardiovascular Study)-0.69 (-0.73 to -0.65)-0.67 (-0.71 to -0.63)-0.19 (-0.23 to -0.15)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in the least squares means: -0.48 · 95% CI -0.54 to -0.43Model included fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in the least squares means: -0.50 · 95% CI -0.55 to -0.45Model included fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in A1C at Month 24 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 24 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 24
Reported as:
Least squares mean · A1C Percentage
Change From Baseline in A1C at Month 24 (Overall Cardiovascular Study)
A1C PercentageErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in A1C at Month 24 (Overall Cardiovascular Study)-0.48 (-0.52 to -0.43)-0.46 (-0.50 to -0.41)-0.08 (-0.14 to -0.03)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Constrained longitudinal data analysis · p = <0.001 (Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.37 · 95% CI -0.45 to -0.30Ertugliflozin vs. Placebo
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 (Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in least squares means: -0.39 · 95% CI -0.46 to -0.32Ertugliflozin vs. Placebo.
SecondaryChange From Baseline in A1C at Month 36 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 36 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 36
Reported as:
Mean · A1C Percentage
Change From Baseline in A1C at Month 36 (Overall Cardiovascular Study)
A1C PercentageErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in A1C at Month 36 (Overall Cardiovascular Study)-0.42 (-0.47 to -0.37)-0.38 (-0.43 to -0.33)-0.04 (-0.10 to 0.01)
SecondaryChange From Baseline in A1C at Month 48 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 48 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 48
Reported as:
Least squares mean · A1C Percentage
Change From Baseline in A1C at Month 48 (Overall Cardiovascular Study)
A1C PercentageErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in A1C at Month 48 (Overall Cardiovascular Study)-0.22 (-0.29 to -0.15)-0.17 (-0.24 to -0.10)0.14 (0.07 to 0.22)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = 0.001 (Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.31 · 95% CI -0.41 to -0.21
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA model · p = <0.001 (Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.36 · 95% CI -0.46 to -0.26
SecondaryChange From Baseline in A1C at Month 60 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 60 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 60
Reported as:
Mean · A1C Percentage
Change From Baseline in A1C at Month 60 (Overall Cardiovascular Study)
A1C PercentageErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in A1C at Month 60 (Overall Cardiovascular Study)-0.25 (-0.35 to -0.15)-0.28 (-0.38 to -0.18)-0.10 (-0.20 to 0.00)
SecondaryChange From Baseline in A1C at Month 72 (Overall Cardiovascular Study)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 72 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 72
Reported as:
Mean · A1C Percentage
Change From Baseline in A1C at Month 72 (Overall Cardiovascular Study)
A1C PercentageErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in A1C at Month 72 (Overall Cardiovascular Study)-0.35 (-0.89 to 0.20)-0.13 (-0.99 to 0.74)0.24 (-0.74 to 1.23)
SecondaryPercentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Overall Cardiovascular Study)28.428.215.5
SecondaryPercentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 52 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 52 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 52 (Overall Cardiovascular Study)28.329.017.4
SecondaryPercentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 24 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Month 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 24 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 24 (Overall Cardiovascular Study)23.923.816.6
SecondaryPercentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 36 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Month 36
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 36 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 36 (Overall Cardiovascular Study)23.122.716.9
SecondaryPercentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 48 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Month 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 48 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 48 (Overall Cardiovascular Study)24.922.718.2
SecondaryPercentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 60 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Month 60
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 60 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 60 (Overall Cardiovascular Study)18.620.016.5
SecondaryPercentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 18 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 18 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 18 (Overall Cardiovascular Study)9.08.84.7
SecondaryPercentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 52 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 52 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 52 (Overall Cardiovascular Study)9.410.96.1
SecondaryPercentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 24 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Month 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 24 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 24 (Overall Cardiovascular Study)9.28.65.8
SecondaryPercentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 36 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Month 36
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 36 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 36 (Overall Cardiovascular Study)7.98.05.8
SecondaryPercentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 48 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Month 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 48 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 48 (Overall Cardiovascular Study)8.19.17.5
SecondaryPercentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 60 (Overall Cardiovascular Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Month 60
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 60 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 60 (Overall Cardiovascular Study)5.39.56.5
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)

FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)-32.18 (-33.76 to -30.61)-34.64 (-36.21 to -33.08)-17.08 (-18.69 to -15.48)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · CLDA · p = <0.001 · Difference in the least squares means: -17.56 · 95% CI -19.49 to -15.63cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -15.10 · 95% CI -17.03 to -13.17cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 52 (Overall Cardiovascular Study)

FPG was analyzed after an overnight fast. This change from baseline reflects the Week 52 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Week 52
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 (Overall Cardiovascular Study)-28.63 (-30.52 to -26.74)-28.97 (-30.78 to -27.15)-8.76 (-10.75 to -6.77)
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Month 24 (Overall Cardiovascular Study)

FPG was analyzed after an overnight fast. This change from baseline reflects the Month 24 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 24
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 24 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 24 (Overall Cardiovascular Study)-22.09 (-24.39 to -19.80)-24.31 (-26.76 to -21.86)-4.39 (-6.99 to -1.78)
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Month 36 (Overall Cardiovascular Study)

FPG was analyzed after an overnight fast. This change from baseline reflects the Month 36 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 36
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 36 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 36 (Overall Cardiovascular Study)-19.39 (-21.88 to -16.89)-22.59 (-24.96 to -20.21)-3.63 (-6.45 to -0.81)
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Month 48 (Overall Cardiovascular Study)

FPG was analyzed after an overnight fast. This change from baseline reflects the Month 48 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 48
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 48 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 48 (Overall Cardiovascular Study)-15.28 (-18.66 to -11.90)-16.16 (-19.50 to -12.83)3.59 (-0.22 to 7.40)
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Month 60 (Overall Cardiovascular Study)

FPG was analyzed after an overnight fast. This change from baseline reflects the Month 60 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 60
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 60 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 60 (Overall Cardiovascular Study)-13.87 (-18.34 to -9.40)-11.15 (-15.78 to -6.52)-4.69 (-9.72 to 0.34)
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Month 72 (Overall Cardiovascular Study)

FPG was analyzed after an overnight fast. This change from baseline reflects the Month 72 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 72
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 72 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 72 (Overall Cardiovascular Study)-2.46 (-31.28 to 26.36)-84.83 (-127.31 to -42.35)14.56 (-23.11 to 52.22)
SecondaryTime to the First Occurrence of a Participant Receiving Glycemic Rescue Therapy Through Week 18 (Overall Cardiovascular Study)

Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.

Time frame:
Up to 18 weeks
Reported as:
Median · Days
Time to the First Occurrence of a Participant Receiving Glycemic Rescue Therapy Through Week 18 (Overall Cardiovascular Study)
DaysErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Time to the First Occurrence of a Participant Receiving Glycemic Rescue Therapy Through Week 18 (Overall Cardiovascular Study)59.0 (36 to 99)51.0 (18 to 91)74.0 (37 to 97)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Log Rank · p = <0.001Log-Rank Test for the comparison to Placebo was based on all data (including for those participants who never had the event).
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Log Rank · p = <0.001Log-Rank Test for the comparison to Placebo was based on all data (including for those participants who never had the event).
SecondaryTime to Initiation of Insulin for Participants Not on Insulin at Baseline (Overall Cardiovascular Study)

Participants who were not on insulin therapy at the start of study medication.

Time frame:
Up to approximately 6 years
Reported as:
Median · Days
Time to Initiation of Insulin for Participants Not on Insulin at Baseline (Overall Cardiovascular Study)
DaysErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Time to Initiation of Insulin for Participants Not on Insulin at Baseline (Overall Cardiovascular Study)602 (8 to 1850)650 (16 to 1934)482 (10 to 1838)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Log Rank · p = <0.001Log-Rank Test for the comparison to Placebo was based on all data (including for those participants who never had the event).
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Log Rank · p = <0.001Log-Rank Test for the comparison to Placebo was based on all data (including for those participants who never had the event).
SecondaryBaseline Insulin Dose for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

Baseline reflects Week 0 insulin dose.

Time frame:
Baseline
Reported as:
Mean · Units/Day
Baseline Insulin Dose for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
Units/DayErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Baseline Insulin Dose for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)63.82 ± 48.1162.15 ± 44.4665.74 ± 46.34
SecondaryChange From Baseline in Insulin Dose at Week 18 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

Time frame:
Baseline and Week 18
Reported as:
Mean · Units/Day
Change From Baseline in Insulin Dose at Week 18 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
Units/DayErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Insulin Dose at Week 18 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)1.05 (0.29 to 1.82)0.81 (-0.10 to 1.71)3.71 (2.72 to 4.70)
SecondaryChange From Baseline in Insulin Dose at Week 52 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

This change from baseline reflects the Week 52 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

Time frame:
Baseline and Week 52
Reported as:
Mean · Units/Day
Change From Baseline in Insulin Dose at Week 52 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
Units/DayErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Insulin Dose at Week 52 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)0.84 (-0.15 to 1.82)-1.69 (-2.83 to -0.54)5.57 (4.16 to 6.98)
SecondaryChange From Baseline in Insulin Dose at Month 24 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

This change from baseline reflects the Month 24 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

Time frame:
Baseline and Month 24
Reported as:
Mean · Units/Day
Change From Baseline in Insulin Dose at Month 24 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
Units/DayErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Insulin Dose at Month 24 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)0.45 (-0.72 to 1.63)-1.58 (-2.95 to -0.21)6.16 (4.47 to 7.85)
SecondaryChange From Baseline in Insulin Dose at Month 36 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

This change from baseline reflects the Month 36 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

Time frame:
Baseline and Month 36
Reported as:
Mean · Units/Day
Change From Baseline in Insulin Dose at Month 36 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
Units/DayErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Insulin Dose at Month 36 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)1.64 (-0.77 to 4.05)-1.92 (-4.31 to 0.46)7.99 (4.65 to 11.34)
SecondaryChange From Baseline in Insulin Dose at Month 48 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

This change from baseline reflects the Month 48 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

Time frame:
Baseline and Month 48
Reported as:
Mean · Units/Day
Change From Baseline in Insulin Dose at Month 48 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
Units/DayErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Insulin Dose at Month 48 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)2.96 (0.41 to 5.51)-1.87 (-4.80 to 1.05)7.28 (3.66 to 10.91)
SecondaryChange From Baseline in Insulin Dose at Month 60 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)

This change from baseline reflects the Month 60 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.

Time frame:
Baseline and Month 60
Reported as:
Mean · Units/Day
Change From Baseline in Insulin Dose at Month 60 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
Units/DayErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Insulin Dose at Month 60 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)-2.47 (-9.65 to 4.72)-1.77 (-11.95 to 8.42)9.42 (1.46 to 17.39)
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)

This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)-2.51 (-3.00 to -2.02)-2.75 (-3.24 to -2.26)0.03 (-0.48 to 0.53)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.78 · 95% CI -3.45 to -2.10The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.53 · 95% CI -3.21 to -1.86The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 (Overall Cardiovascular Study)

This change from baseline reflects the Week 52 sitting SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 (Overall Cardiovascular Study)-1.84 (-2.35 to -1.32)-2.41 (-2.92 to -1.89)0.75 (0.23 to 1.26)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares mean: -3.15 · 95% CI -3.85 to -2.45The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.58 · 95% CI -3.28 to -1.89The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 24 (Overall Cardiovascular Study)

This change from baseline reflects the Month 24 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 24
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 24 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 24 (Overall Cardiovascular Study)-1.80 (-2.42 to -1.19)-1.82 (-2.44 to -1.19)0.90 (0.27 to 1.53)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.72 · 95% CI -3.57 to -1.86The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.70 · 95% CI -3.56 to -1.85The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 36 (Overall Cardiovascular Study)

This change from baseline reflects the Month 36 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 36
Reported as:
Mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 36 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 36 (Overall Cardiovascular Study)-1.55 ± 14.56-1.21 ± 15.050.84 ± 14.63
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 48 (Overall Cardiovascular Study)

This change from baseline reflects the Month 48 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 48
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 48 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 48 (Overall Cardiovascular Study)-2.07 (-2.84 to -1.31)-2.26 (-3.03 to -1.49)0.53 (-0.27 to 1.33)
Statistical analysis
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.60 · 95% CI -3.68 to -1.52The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.79 · 95% CI -3.87 to -1.71The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 60 (Overall Cardiovascular Study)

This change from baseline reflects the Month 60 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 60
Reported as:
Mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 60 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 60 (Overall Cardiovascular Study)-2.18 ± 15.39-1.87 ± 15.010.62 ± 15.85
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 72 (Overall Cardiovascular Study)

This change from baseline reflects the Month 72 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 72
Reported as:
Mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 72 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 72 (Overall Cardiovascular Study)1.28 (-7.63 to 10.20)-3.46 (-10.91 to 3.99)2.72 (-5.95 to 11.40)
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)

This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)-0.99 (-1.29 to -0.70)-1.08 (-1.38 to -0.79)-0.12 (-0.42 to 0.18)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -0.96 · 95% CI -1.37 to -0.56cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least means squares: -0.87 · 95% CI -1.28 to -0.47cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 52 (Overall Cardiovascular Study)

This change from baseline reflects the Week 52 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 52 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 52 (Overall Cardiovascular Study)-0.97 (-1.28 to -0.67)-0.95 (-1.26 to -0.65)-0.15 (-0.45 to 0.16)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -0.81 · 95% CI -1.22 to -0.39The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -0.83 · 95% CI -1.24 to -0.41The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 24 (Overall Cardiovascular Study)

This change from baseline reflects the Month 24 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 24
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 24 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 24 (Overall Cardiovascular Study)-0.94 (-1.31 to -0.57)-0.90 (-1.27 to -0.53)-0.23 (-0.60 to 0.15)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = 0.010 · Difference in the least squares means: -0.67 · 95% CI -1.19 to -0.16The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = 0.006 · Difference in the least squares means: -0.71 · 95% CI -1.22 to -0.20The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 36 (Overall Cardiovascular Study)

This change from baseline reflects the Month 36 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 36
Reported as:
Mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 36 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 36 (Overall Cardiovascular Study)-1.27 ± 8.94-0.92 ± 8.89-0.22 ± 9.15
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 48 (Overall Cardiovascular Study)

This change from baseline reflects the Month 48 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 48
Reported as:
Mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 48 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 48 (Overall Cardiovascular Study)-1.45 (-1.93 to -0.97)-1.42 (-1.90 to -0.94)-0.64 (-1.14 to -0.14)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Constrained longitudinal data analysis · p = 0.024 (cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.78 · 95% CI -1.46 to -0.10
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Constrained longitudinal data analysis · p = 0.020 (cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.81 · 95% CI -1.48 to -0.13
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 60 (Overall Cardiovascular Study)

This change from baseline reflects the Month 60 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 60
Reported as:
Mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 60 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 60 (Overall Cardiovascular Study)-1.82 ± 8.66-1.43 ± 9.36-1.26 ± 9.38
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 72 (Overall Cardiovascular Study)

This change from baseline reflects the Month 72 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 72
Reported as:
Mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 72 (Overall Cardiovascular Study)
mmHgErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 72 (Overall Cardiovascular Study)-2.18 (-7.65 to 3.29)1.86 (-2.73 to 6.45)7.29 (1.63 to 12.94)
SecondaryChange From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)

This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)
KilogramsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)-2.03 (-2.14 to -1.92)-2.32 (-2.43 to -2.22)-0.40 (-0.51 to -0.30)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -1.92 · 95% CI -2.07 to -1.77cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -1.63 · 95% CI -1.78 to -1.47cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Body Weight at Week 52 (Overall Cardiovascular Study)

This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 52 (Overall Cardiovascular Study)
KilogramsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Body Weight at Week 52 (Overall Cardiovascular Study)-2.46 (-2.61 to -2.31)-2.84 (-2.99 to -2.69)-0.39 (-0.54 to -0.24)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.45 · 95% CI -2.67 to -2.24cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.07 · 95% CI -2.28 to -1.86cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Body Weight at Month 24 (Overall Cardiovascular Study)

This change from baseline reflects the Month 24 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 24
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Month 24 (Overall Cardiovascular Study)
KilogramsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Body Weight at Month 24 (Overall Cardiovascular Study)-2.75 (-2.95 to -2.56)-3.17 (-3.39 to -2.95)-0.65 (-0.85 to -0.44)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.53 · 95% CI -2.83 to -2.22cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.11 · 95% CI -2.39 to -1.83cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Body Weight at Month 36 (Overall Cardiovascular Study)

This change from baseline reflects the Month 36 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 36
Reported as:
Mean · Kilograms
Change From Baseline in Body Weight at Month 36 (Overall Cardiovascular Study)
KilogramsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Body Weight at Month 36 (Overall Cardiovascular Study)-3.03 (-3.24 to -2.82)-3.41 (-3.63 to -3.20)-0.98 (-1.20 to -0.77)
SecondaryChange From Baseline in Body Weight at Month 48 (Overall Cardiovascular Study)

This change from baseline reflects the Month 48 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 48
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Month 48 (Overall Cardiovascular Study)
KilogramsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Body Weight at Month 48 (Overall Cardiovascular Study)-3.39 (-3.69 to -3.10)-3.83 (-4.14 to -3.51)-1.29 (-1.59 to -1.00)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.53 · 95% CI -2.97 to -2.10cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · cLDA · p = <0.001 · Difference in the least squares means: -2.10 · 95% CI -2.52 to -1.68cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Body Weight at Month 60 (Overall Cardiovascular Study)

This change from baseline reflects the Month 60 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 60
Reported as:
Mean · Kilograms
Change From Baseline in Body Weight at Month 60 (Overall Cardiovascular Study)
KilogramsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Body Weight at Month 60 (Overall Cardiovascular Study)-3.66 (-4.11 to -3.20)-4.58 (-5.06 to -4.11)-1.21 (-1.63 to -0.78)
SecondaryChange From Baseline in Body Weight at Month 72 (Overall Cardiovascular Study)

This change from baseline reflects the Month 72 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 72
Reported as:
Mean · Kilograms
Change From Baseline in Body Weight at Month 72 (Overall Cardiovascular Study)
KilogramsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Body Weight at Month 72 (Overall Cardiovascular Study)-4.18 (-7.83 to -0.53)-7.37 (-12.67 to -2.07)-0.98 (-4.13 to 2.18)
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 18 (Overall Cardiovascular Study)

This change from baseline reflects the Week 18 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 18 (Overall Cardiovascular Study)
mL/min/1.73 m^2Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 18 (Overall Cardiovascular Study)-1.22 (-1.66 to -0.77)-1.81 (-2.26 to -1.36)-0.03 (-0.48 to 0.42)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) · Difference in the lease squares means: -1.78 · 95% CI -2.41 to -1.15
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Difference in the least squares means: -1.19 · 95% CI -1.82 to -0.56
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52 (Overall Cardiovascular Study)

This change from baseline reflects the Week 52 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52 (Overall Cardiovascular Study)
mL/min/1.73 m^2Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52 (Overall Cardiovascular Study)-0.51 (-1.01 to -0.02)-1.18 (-1.67 to -0.68)-0.30 (-0.80 to 0.20)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) · Difference in the lease squares means: -0.88 · 95% CI -1.58 to -0.18
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Difference in the least squares means: -0.21 · 95% CI -0.91 to 0.49
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 24 (Overall Cardiovascular Study)

This change from baseline reflects the Month 24 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.

Time frame:
Baseline and Month 24
Reported as:
Mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 24 (Overall Cardiovascular Study)
mL/min/1.73 m^2Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 24 (Overall Cardiovascular Study)-1.48 (-2.07 to -0.90)-2.35 (-2.94 to -1.76)-2.60 (-3.20 to -2.01)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Difference in the least squares means: 0.25 · 95% CI -0.59 to 1.08Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Difference in the least squares means: 1.12 · 95% CI 0.28 to 1.95Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 36 (Overall Cardiovascular Study)

This change from baseline reflects the Month 36 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.

Time frame:
Baseline and Month 36
Reported as:
Mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 36 (Overall Cardiovascular Study)
mL/min/1.73 m^2Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 36 (Overall Cardiovascular Study)-2.4 ± 14.0-2.3 ± 13.4-3.8 ± 14.1
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 48 (Overall Cardiovascular Study)

This change from baseline reflects the Month 48 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.

Time frame:
Baseline and Month 48
Reported as:
Least squares mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 48 (Overall Cardiovascular Study)
mL/min/1.73 m^2Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 48 (Overall Cardiovascular Study)-2.75 (-3.56 to -1.94)-2.93 (-3.73 to -2.13)-4.41 (-5.27 to -3.55)
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) · Difference in the lease squares means: 1.48 · 95% CI 0.31 to 2.66
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Difference in the least squares means: 1.66 · 95% CI 0.49 to 2.84
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 60 (Overall Cardiovascular Study)

This change from baseline reflects the Month 60 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.

Time frame:
Baseline and Month 60
Reported as:
Mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 60 (Overall Cardiovascular Study)
mL/min/1.73 m^2Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 60 (Overall Cardiovascular Study)-2.4 ± 15.4-2.9 ± 14.1-6.8 ± 14.3
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 72 (Overall Cardiovascular Study)

This change from baseline reflects the Month 72 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.

Time frame:
Baseline and Month 72
Reported as:
Mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 72 (Overall Cardiovascular Study)
mL/min/1.73 m^2Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 72 (Overall Cardiovascular Study)3.7 ± 12.90.2 ± 12.2-1.8 ± 14.1
SecondaryBaseline Serum Creatinine (Overall Cardiovascular Study)

Baseline reflects Week 0 serum creatinine.

Time frame:
Baseline
Reported as:
Mean · mg/dL
Baseline Serum Creatinine (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)All Ertugliflozin (Overall Cardiovascular Study)
Baseline Serum Creatinine (Overall Cardiovascular Study)0.992 ± 0.2780.985 ± 0.2770.991 ± 0.2810.998 ± 0.278
SecondaryChange From Baseline in Serum Creatinine at Week 18 (Overall Cardiovascular Study)

This change from baseline reflects the Week 18 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Week 18
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 18 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Serum Creatinine at Week 18 (Overall Cardiovascular Study)0.022 ± 0.1540.032 ± 0.148-0.002 ± 0.138
SecondaryChange From Baseline in Serum Creatinine at Week 52 (Overall Cardiovascular Study)

This change from baseline reflects the Week 52 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Week 52
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 52 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Serum Creatinine at Week 52 (Overall Cardiovascular Study)0.013 ± 0.1660.023 ± 0.1630.004 ± 0.156
SecondaryChange From Baseline in Serum Creatinine at Month 24 (Overall Cardiovascular Study)

This change from baseline reflects the Month 24 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 24
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Month 24 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Serum Creatinine at Month 24 (Overall Cardiovascular Study)0.024 ± 0.1760.035 ± 0.1870.034 ± 0.197
SecondaryChange From Baseline in Serum Creatinine at Month 36 (Overall Cardiovascular Study)

This change from baseline reflects the Month 36 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 36
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Month 36 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Serum Creatinine at Month 36 (Overall Cardiovascular Study)0.037 ± 0.1940.035 ± 0.1880.049 ± 0.194
SecondaryChange From Baseline in Serum Creatinine at Month 48 (Overall Cardiovascular Study)

This change from baseline reflects the Month 48 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 48
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Month 48 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Serum Creatinine at Month 48 (Overall Cardiovascular Study)0.032 ± 0.2060.036 ± 0.1960.059 ± 0.210
SecondaryChange From Baseline in Serum Creatinine at Month 60 (Overall Cardiovascular Study)

This change from baseline reflects the Month 60 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 60
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Month 60 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Serum Creatinine at Month 60 (Overall Cardiovascular Study)0.027 ± 0.2020.042 ± 0.2160.098 ± 0.248
SecondaryChange From Baseline in Serum Creatinine at Month 72 (Overall Cardiovascular Study)

This change from baseline reflects the Month 72 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 72
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Month 72 (Overall Cardiovascular Study)
mg/dLErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Change From Baseline in Serum Creatinine at Month 72 (Overall Cardiovascular Study)-0.034 ± 0.1760.001 ± 0.120-0.013 ± 0.162
SecondaryBaseline Urinary Albumin/Creatinine Ratio (Overall Cardiovascular Study)

Baseline reflects Week 0 albumin/creatinine ratio.

Time frame:
Baseline
Reported as:
Median · mg/g
Baseline Urinary Albumin/Creatinine Ratio (Overall Cardiovascular Study)
mg/gErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Baseline Urinary Albumin/Creatinine Ratio (Overall Cardiovascular Study)18.00 (6.00 to 68.00)19.00 (6.00 to 69.00)19.00 (6.00 to 66.50)
SecondaryPercent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 18 (Overall Cardiovascular Study)

This percent change relative to baseline reflects the Week 18 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Week 18
Reported as:
Median · Percent Change
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 18 (Overall Cardiovascular Study)
Percent ChangeErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 18 (Overall Cardiovascular Study)-13.40 (-53.52 to 50.00)-14.71 (-55.53 to 50.00)0.00 (-44.44 to 66.67)
SecondaryPercent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 52 (Overall Cardiovascular Study)

This percent change relative to baseline reflects the Week 52 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Week 52
Reported as:
Median · Percent Change
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 52 (Overall Cardiovascular Study)
Percent ChangeErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 52 (Overall Cardiovascular Study)-2.53 (-50.00 to 66.67)-6.82 (-50.00 to 66.67)5.41 (-40.00 to 96.34)
SecondaryPercent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 24 (Overall Cardiovascular Study)

This percent change relative to baseline reflects the Month 24 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 24
Reported as:
Median · Percent Change
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 24 (Overall Cardiovascular Study)
Percent ChangeErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 24 (Overall Cardiovascular Study)-0.73 (-48.96 to 100.00)1.06 (-47.78 to 95.26)17.14 (-38.00 to 140.00)
SecondaryPercent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 36 (Overall Cardiovascular Study)

This percent change relative to baseline reflects the Month 36 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 36
Reported as:
Median · Percent Change
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 36 (Overall Cardiovascular Study)
Percent ChangeErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 36 (Overall Cardiovascular Study)13.33 (-49.34 to 120.37)3.33 (-49.44 to 100.00)27.03 (-38.46 to 177.78)
SecondaryPercent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 48 (Overall Cardiovascular Study)

This percent change relative to baseline reflects the Month 48 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 48
Reported as:
Median · Percent Change
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 48 (Overall Cardiovascular Study)
Percent ChangeErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 48 (Overall Cardiovascular Study)33.33 (-36.84 to 200.00)21.25 (-42.86 to 150.00)50.00 (-33.33 to 227.27)
SecondaryPercent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 60 (Overall Cardiovascular Study)

This percent change relative to baseline reflects the Month 60 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.

Time frame:
Baseline and Month 60
Reported as:
Median · Percent Change
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 60 (Overall Cardiovascular Study)
Percent ChangeErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 60 (Overall Cardiovascular Study)30.99 (-40.00 to 200.00)20.00 (-45.83 to 150.00)48.53 (-28.57 to 222.41)
SecondaryPercentage of Participants With Albuminuria Progression or Regression at Week 18 (Overall Cardiovascular Study)

Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal-albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

Time frame:
Week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants With Albuminuria Progression or Regression at Week 18 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants with albuminuria progression7.67.710.8
Percentage of Participants with albuminuria regression14.914.710.7
SecondaryPercentage of Participants With Albuminuria Progression or Regression at Week 52 (Overall Cardiovascular Study)

Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Albuminuria Progression or Regression at Week 52 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants with albuminuria progression9.510.212.9
Percentage of Participants with albuminuria regression14.614.810.2
SecondaryPercentage of Participants With Albuminuria Progression or Regression at Month 24 (Overall Cardiovascular Study)

Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

Time frame:
Month 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Albuminuria Progression or Regression at Month 24 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants with albuminuria progression12.111.016.9
Percentage of Participants with albuminuria regression14.313.89.9
SecondaryPercentage of Participants With Albuminuria Progression or Regression at Month 36 (Overall Cardiovascular Study)

Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

Time frame:
Month 36
Reported as:
Number · Percentage of Participants
Percentage of Participants With Albuminuria Progression or Regression at Month 36 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Participants with albuminuria progression14.612.518.1
Participants with albuminuria regression13.814.311.0
SecondaryPercentage of Participants With Albuminuria Progression or Regression at Month 48 (Overall Cardiovascular Study)

Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline and normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

Time frame:
Month 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Albuminuria Progression or Regression at Month 48 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants with albuminuria progression19.514.921.5
Percentage of Participants with albuminuria regression11.612.29.9
SecondaryPercentage of Participants With Albuminuria Progression or Regression at Month 60 (Overall Cardiovascular Study)

Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).

Time frame:
Month 60
Reported as:
Number · Percentage of Participants
Percentage of Participants With Albuminuria Progression or Regression at Month 60 (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants with albuminuria progression18.614.722.1
Percentage of Participants with albuminuria regression11.314.810.5
SecondaryPercentage of Participants Experiencing an Adverse Event (AE) (Overall Cardiovascular Study)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to approximately 6 years
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing an Adverse Event (AE) (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants Experiencing an Adverse Event (AE) (Overall Cardiovascular Study)85.884.685.6
Statistical analysis
  • Ertugliflozin 15 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Difference in % vs placebo: -0.9 · 95% CI -2.8 to 0.9
  • Ertugliflozin 5 mg (Overall Cardiovascular Study) vs Placebo (Overall Cardiovascular Study) · Difference in % vs placebo: 0.3 · 95% CI -1.6 to 2.1
SecondaryPercentage of Participants Experiencing an Adverse Event (AE) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 18 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing an Adverse Event (AE) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
Percentage of ParticipantsErtugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Insulin +/- Metformin Glycemic Sub-study)
Percentage of Participants Experiencing an Adverse Event (AE) (Insulin With or Without Metformin Add-on Glycemic Sub-study)59.262.461.1
Statistical analysis
  • Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · Difference in % vs placebo: 1.3 · 95% CI -5.8 to 8.4
  • Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · Difference in % vs placebo: -1.9 · 95% CI -9.2 to 5.4
SecondaryPercentage of Participants Experiencing an Adverse Event (AE) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 18 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing an Adverse Event (AE) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
Percentage of ParticipantsErtugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)
Percentage of Participants Experiencing an Adverse Event (AE) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)47.325.945.8
Statistical analysis
  • Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) · Difference in % vs placebo: 1.4 · 95% CI -17.7 to 20.4
  • Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) · Difference in % vs placebo: -19.9 · 95% CI -37.5 to -1.2
SecondaryPercentage of Participants Experiencing an Adverse Event (AE) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 18 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing an Adverse Event (AE) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
Percentage of ParticipantsErtugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)Placebo (Metformin With Sulfonylurea Glycemic Sub-study)
Percentage of Participants Experiencing an Adverse Event (AE) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)48.054.947.0
Statistical analysis
  • Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · Difference in % vs placebo: 7.9 · 95% CI -5.1 to 20.5
  • Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · Difference in % vs placebo: 1.0 · 95% CI -12.3 to 14.2
SecondaryPercentage of Participants Discontinuing Study Treatment Due to An AE (Overall Cardiovascular Study)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to approximately 6 years
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Study Treatment Due to An AE (Overall Cardiovascular Study)
Percentage of ParticipantsErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)
Percentage of Participants Discontinuing Study Treatment Due to An AE (Overall Cardiovascular Study)7.57.36.8
SecondaryPercentage of Participants Discontinuing Study Treatment Due to An AE (Insulin With or Without Metformin Add-on Glycemic Sub-study)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 18 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Study Treatment Due to An AE (Insulin With or Without Metformin Add-on Glycemic Sub-study)
Percentage of ParticipantsErtugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Insulin +/- Metformin Glycemic Sub-study)
Percentage of Participants Discontinuing Study Treatment Due to An AE (Insulin With or Without Metformin Add-on Glycemic Sub-study)2.93.83.7
Statistical analysis
  • Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · Difference in % vs placebo: 0.0 · 95% CI -2.9 to 3.0
  • Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · Difference in % vs placebo: -1.2 · 95% CI -4.0 to 1.6
SecondaryPercentage of Participants Discontinuing Study Treatment Due to An AE (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 18 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Study Treatment Due to An AE (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
Percentage of ParticipantsErtugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)
Percentage of Participants Discontinuing Study Treatment Due to An AE (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)3.61.92.1
SecondaryPercentage of Participants Discontinuing Study Treatment Due to An AE (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 18 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Study Treatment Due to An AE (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
Percentage of ParticipantsErtugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)Placebo (Metformin With Sulfonylurea Glycemic Sub-study)
Percentage of Participants Discontinuing Study Treatment Due to An AE (Metformin With Sulfonylurea Add-on Glycemic Sub-study)02.71.7
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in the FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
mg/dLErtugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Insulin +/- Metformin Glycemic Sub-study)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)-26.98 (-32.80 to -21.17)-33.15 (-38.81 to -27.48)-7.74 (-13.67 to -1.81)
Statistical analysis
  • Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · CLDA · p = <0.001 · Difference in the least squares means: -25.40 · 95% CI -32.84 to -17.96Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · cLDA · p = <0.001 · Difference in the least squares means: -19.24 · 95% CI -26.80 to -11.68Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin) and the interaction of time by treatment.
SecondaryChange From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
KilogramsErtugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Insulin +/- Metformin Glycemic Sub-study)
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)-1.87 (-2.22 to -1.52)-2.13 (-2.47 to -1.79)-0.25 (-0.60 to 0.11)
Statistical analysis
  • Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · cLDA · p = <0.001 · Difference in the least squares means: -1.88 · 95% CI -2.37 to -1.13Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) · cLDA model · p = <0.001 · Difference in the least squares means: -1.62 · 95% CI -2.12 to -1.13Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin) and the interaction of time by treatment.
SecondaryPercentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
Percentage of ParticipantsErtugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Insulin +/- Metformin Glycemic Sub-study)
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)20.721.110.7
Statistical analysis
  • Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · Regression, Logistic · p = <0.001 · Adjusted odds ratio relative to placebo: 2.49 · 95% CI 1.61 to 3.83Model fitted with fixed effects for treatment, stratum for insulin sub-study, covariates for baseline A1C and baseline eGFR (continuous).
  • Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · Regression, Logistic · p = <0.001 · Adjusted odds ratio relative to placebo: 2.60 · 95% CI 1.64 to 4.12Model fitted with fixed effects for treatment, stratum for insulin sub-study, covariates for baseline A1C and baseline eGFR (continuous).
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
mmHgErtugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Insulin +/- Metformin Glycemic Sub-study)
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)-2.67 (-4.17 to -1.18)-2.12 (-3.57 to -0.67)0.20 (-1.33 to 1.74)
Statistical analysis
  • Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · cLDA · p = 0.025 · Difference in the least squares means: -2.32 · 95% CI -4.35 to -0.30Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · cLDA · p = 0.006 · Difference in the least squares means: -2.88 · 95% CI -4.94 to -0.82Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)

This change from baseline reflects the Week 18 DBP minus the Week 0 BBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
mmHgErtugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Insulin +/- Metformin Glycemic Sub-study)
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)-0.86 (-1.72 to -0.00)-0.64 (-1.47 to 0.20)-0.26 (-1.14 to 0.62)
Statistical analysis
  • Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · cLDA model · p = 0.533 · Difference in the least squares means: -0.38 · 95% CI -1.56 to 0.81Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) vs Placebo (Insulin +/- Metformin Glycemic Sub-study) · cLDA model · p = 0.326 · Difference in the least squares means: -0.60 · 95% CI -1.81 to 0.60Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.
SecondaryBaseline Insulin Dose for Participants Receiving Insulin at Baseline - (Insulin With or Without Metformin Add-on Glycemic Sub-study)

Baseline reflects Week 0 insulin dose.

Time frame:
Baseline
Reported as:
Mean · Unit/day
Baseline Insulin Dose for Participants Receiving Insulin at Baseline - (Insulin With or Without Metformin Add-on Glycemic Sub-study)
Unit/dayErtugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Insulin +/- Metformin Glycemic Sub-study)
Baseline Insulin Dose for Participants Receiving Insulin at Baseline - (Insulin With or Without Metformin Add-on Glycemic Sub-study)70.76 ± 44.1567.29 ± 41.2373.20 ± 49.58
SecondaryChange From Baseline at Week 18 in Insulin Dose for Participants Receiving Insulin at Baseline - Including Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)

This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a decrease in insulin dose. Participants who met glycemic rescue criteria received glycemic rescue medication. "Including rescue", included data following the initiation of rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Mean · Unit/day
Change From Baseline at Week 18 in Insulin Dose for Participants Receiving Insulin at Baseline - Including Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)
Unit/dayErtugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Insulin +/- Metformin Glycemic Sub-study)
Change From Baseline at Week 18 in Insulin Dose for Participants Receiving Insulin at Baseline - Including Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)-0.71 ± 10.14-2.14 ± 10.23-0.29 ± 11.49
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
mg/dLErtugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)-28.28 (-39.44 to -17.12)-26.97 (-38.51 to -15.44)-14.76 (-26.43 to -3.08)
Statistical analysis
  • Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) · cLDA · p = 0.105 · Difference in the least squares means: -12.22 · 95% CI -27.03 to 2.06cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) · cLDA · p = 0.068 · Difference in the least squares means: -13.53 · 95% CI -28.06 to 1.00cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.
SecondaryChange From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
KilogramsErtugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)-1.75 (-2.61 to -0.89)-1.20 (-2.09 to -0.31)-0.68 (-1.60 to 0.25)
Statistical analysis
  • Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) · cLDA · p = 0.418 · Difference in the least squares means: -0.52 · 95% CI -1.79 to 0.75Model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) · cLDA model · p = 0.092 · Difference in the least squares means: -1.07 · 95% CI -2.32 to 0.18Model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryPercentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
Percentage of ParticipantsErtugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)32.727.825.0
Statistical analysis
  • Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) · Regression, Logistic · p = 0.460 · Odds ratio relative to placebo: 1.48 · 95% CI 0.52 to 4.17Model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR (continuous).
  • Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) · Regression, Logistic · p = 0.335 · Odds ratio relative to placebo: 1.62 · 95% CI 0.61 to 4.35Model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR (continuous).
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
mmHgErtugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)-0.72 (-4.06 to 2.63)-0.80 (-4.23 to 2.63)-3.53 (-7.03 to -0.02)
Statistical analysis
  • Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) · cLDA · p = 0.255 · Difference in the least squares means: 2.73 · 95% CI -2.00 to 7.45The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) · cLDA · p = 0.235 · Difference in the least squares means: 2.81 · 95% CI -1.85 to 7.48The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)

This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
mmHgErtugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)
Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)-1.18 (-3.24 to 0.88)-0.93 (-3.05 to 1.18)-2.91 (-5.06 to -0.76)
Statistical analysis
  • Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) · cLDA model · p = 0.178 · Difference in the least squares means: 1.98 · 95% CI -0.91 to 4.86Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) vs Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) · cLDA · p = 0.230 · Difference in the least squares means: 1.73 · 95% CI -1.11 to 4.58Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
mg/dLErtugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)Placebo (Metformin With Sulfonylurea Glycemic Sub-study)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)-35.28 (-43.05 to -27.50)-36.18 (-43.36 to -28.99)-4.81 (-12.10 to 2.49)
Statistical analysis
  • Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) · CLDA · p = <0.001 · Difference in the least squares means: -31.37 · 95% CI -40.68 to -22.07cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · cLDA · p = <0.001 · Difference in the least squares means: -30.47 · 95% CI -40.23 to -20.72cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.
SecondaryChange From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
KilogramsErtugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)Placebo (Metformin With Sulfonylurea Glycemic Sub-study)
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)-2.04 (-2.58 to -1.50)-2.41 (-2.91 to -1.91)-0.47 (-0.97 to 0.03)
Statistical analysis
  • Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · cLDA · p = <0.001 · Difference in the least squares means: -1.94 · 95% CI -2.65 to -1.24Model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · cLDA · p = <0.001 · Difference in the least squares means: -1.57 · 95% CI -2.30 to -0.84Model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.
SecondaryPercentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
Percentage of ParticipantsErtugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)Placebo (Metformin With Sulfonylurea Glycemic Sub-study)
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)37.032.712.8
Statistical analysis
  • Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · Regression, Logistic · p = <0.001 · Adjusted odds ratio relative to placebo: 4.10 · 95% CI 2.00 to 8.42Model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR (continuous).
  • Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · Regression, Logistic · p = <0.001 · Adjusted odds ratio relative to placebo: 5.97 · 95% CI 2.86 to 12.49Model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR (continuous).
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
mmHgErtugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)Placebo (Metformin With Sulfonylurea Glycemic Sub-study)
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)-2.26 (-4.78 to 0.25)-1.54 (-3.85 to 0.77)-0.70 (-3.04 to 1.64)
Statistical analysis
  • Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · cLDA · p = 0.597 · Difference in the least squares means: -0.85 · 95% CI -4.00 to 2.30The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · cLDA · p = 0.351 · Difference in the least squares means: -1.57 · 95% CI -4.87 to 1.73The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
SecondaryChange From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)

This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
mmHgErtugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)Placebo (Metformin With Sulfonylurea Glycemic Sub-study)
Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)-0.30 (-1.80 to 1.21)-0.92 (-2.30 to 0.46)-0.24 (-1.64 to 1.15)
Statistical analysis
  • Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · cLDA · p = 0.490 · Difference in the least squares means: -0.68 · 95% CI -2.60 to 1.25Model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.
  • Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) vs Placebo (Metformin With Sulfonylurea Glycemic Sub-study) · cLDA · p = 0.958 · Difference in the least squares means: -0.05 · 95% CI -2.07 to 1.96Model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.

Adverse events

Collected over Overall Cardiovascular study - Up to approximately 6 years 3 Glycemic Sub-studies - Up to 18 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ertugliflozin 5 mg (Overall Cardiovascular Study)228/2,746 (8.3%)958/2,746 (34.9%)1,405/2,746 (51.2%)
Ertugliflozin 15 mg (Overall Cardiovascular Study)233/2,747 (8.5%)937/2,747 (34.1%)1,389/2,747 (50.6%)
Placebo (Overall Cardiovascular Study)247/2,745 (9%)990/2,745 (36.1%)1,395/2,745 (50.8%)
Ertugliflozin 5 mg (Insulin +/- Metformin Sub-study)4/348 (1.1%)33/348 (9.5%)127/348 (36.5%)
Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)6/370 (1.6%)27/370 (7.3%)144/370 (38.9%)
Placebo (Insulin +/- Metformin Glycemic Sub-study)1/347 (0.3%)37/347 (10.7%)135/347 (38.9%)
Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)0/55 (0%)4/55 (7.3%)10/55 (18.2%)
Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)1/54 (1.9%)1/54 (1.9%)4/54 (7.4%)
Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study)0/48 (0%)2/48 (4.2%)9/48 (18.8%)
Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)0/100 (0%)7/100 (7%)24/100 (24%)
Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)1/113 (0.9%)8/113 (7.1%)32/113 (28.3%)
Placebo (Metformin With Sulfonylurea Glycemic Sub-study)0/117 (0%)6/117 (5.1%)26/117 (22.2%)
Most frequent serious events
Showing 10 of 1,003
Most frequent serious events
EventErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)Ertugliflozin 5 mg (Insulin +/- Metformin Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study)Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)Placebo (Metformin With Sulfonylurea Glycemic Sub-study)
Angina unstableCardiac disorders74/274671/274789/27453/3481/3701/3470/550/541/480/1002/1130/117
Acute myocardial infarctionCardiac disorders52/274676/274773/27453/3481/3701/3470/550/540/481/1001/1130/117
Ischaemic strokeNervous system disorders29/274640/274741/27451/3480/3701/3470/551/541/480/1000/1130/117
PneumoniaInfections and infestations51/274646/274745/27451/3480/3700/3470/550/540/480/1000/1130/117
Cardiac failure acuteCardiac disorders7/27467/27478/27450/3480/3700/3470/551/540/480/1000/1130/117
Myocardial infarctionCardiac disorders39/274649/274737/27451/3480/3702/3470/551/540/481/1000/1131/117
Acute coronary syndromeCardiac disorders9/27466/27478/27450/3480/3700/3471/550/540/480/1000/1130/117
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/27461/27470/27450/3480/3700/3471/550/540/480/1000/1130/117
DizzinessNervous system disorders2/27462/27474/27450/3480/3700/3471/550/540/480/1000/1130/117
Extremity necrosisVascular disorders2/27466/27474/27450/3480/3700/3471/550/540/480/1000/1130/117
Most frequent other events
Most frequent other events
EventErtugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)Ertugliflozin 5 mg (Insulin +/- Metformin Sub-study)Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)Placebo (Insulin +/- Metformin Glycemic Sub-study)Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study)Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)Placebo (Metformin With Sulfonylurea Glycemic Sub-study)
HypoglycaemiaMetabolism and nutrition disorders883/2746854/2747884/2745101/348112/370109/3473/553/540/4813/10019/11314/117
Urinary tract infectionInfections and infestations256/2746262/2747211/27458/3489/3707/3471/551/540/481/1004/1133/117
NasopharyngitisInfections and infestations178/2746204/2747186/27454/34813/37011/3471/550/542/482/1005/1133/117
Upper respiratory tract infectionInfections and infestations197/2746177/2747203/27458/34810/3709/3470/550/540/483/1002/1134/117
HyperglycaemiaMetabolism and nutrition disorders106/274696/2747178/27455/3489/3706/3470/550/542/483/1002/1131/117
HypertensionVascular disorders133/2746148/2747168/27455/3484/3702/3472/550/542/484/1002/1133/117
Back painMusculoskeletal and connective tissue disorders133/2746138/2747143/27452/3482/3702/3472/550/542/481/1001/1132/117
DizzinessNervous system disorders139/2746141/274789/27458/3489/3704/3471/550/540/482/1004/1131/117
DiarrhoeaGastrointestinal disorders132/2746138/2747126/27457/3489/3708/3470/550/541/482/1003/1130/117

Baseline characteristics

The analysis population is all randomized participants.

Age, Continuous
Age, Continuous(Years)Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)Total
Mean64.3 ± 8.264.4 ± 8.064.4 ± 8.064.4 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)Total
Female8018328442477
Male1951191519035769
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)Total
Hispanic or Latino3533473431043
Not Hispanic or Latino2390239223997181
Unknown or Not Reported98522
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)Total
American Indian or Alaska Native1381738
Asian187149162498
Native Hawaiian or Other Pacific Islander4101529
Black or African American917569235
White2390243624147240
More than one race676970206
Unknown or Not Reported0000
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mg/dL)Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)Total
Mean176.1 ± 52.5174.8 ± 51.6173.6 ± 49.4174.8 ± 51.2
Sitting Systolic Blood Pressure (SBP)
Sitting Systolic Blood Pressure (SBP)(mmHg)Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)Total
Mean133.7 ± 13.7133.2 ± 13.8133.1 ± 13.9133.3 ± 13.8
Sitting Diastolic Blood Pressure (DBP)
Sitting Diastolic Blood Pressure (DBP)(mmHg)Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)Total
Mean76.8 ± 8.576.7 ± 8.276.4 ± 8.776.6 ± 8.5
Body Weight
Body Weight(Kilograms)Ertugliflozin 5 mg (Overall Cardiovascular Study)Ertugliflozin 15 mg (Overall Cardiovascular Study)Placebo (Overall Cardiovascular Study)Total
Mean91.9 ± 18.491.6 ± 18.691.9 ± 18.391.8 ± 18.4

2 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG; VERTIS-CV Investigators. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018 Dec;206:11-23. doi: 10.1016/j.ahj.2018.08.016. Epub 2018 Sep 5. PubMed 30290289 ↗
  • Segar MW, Kolkailah AA, Frederich R, Pong A, Cannon CP, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Liu CC, Maldonado M, Liu J, Cater NB, Pandey A, Cherney DZI. Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2022 Sep;24(9):1829-1839. doi: 10.1111/dom.14769. Epub 2022 Jun 15. PubMed 35603908 ↗
  • Wojeck BS, Inzucchi SE, Neeland IJ, Mancuso JP, Frederich R, Masiukiewicz U, Cater NB, McGuire DK, Cannon CP, Yaggi HK. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep Breath. 2023 May;27(2):669-672. doi: 10.1007/s11325-022-02594-2. Epub 2022 May 20. PubMed 35596030 ↗
  • Dagogo-Jack S, Cannon CP, Cherney DZI, Cosentino F, Liu J, Pong A, Gantz I, Frederich R, Mancuso JP, Pratley RE. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV. Diabetes Obes Metab. 2022 Jul;24(7):1245-1254. doi: 10.1111/dom.14691. Epub 2022 Mar 29. PubMed 35266296 ↗
  • Cherney DZI, Cosentino F, Pratley RE, Dagogo-Jack S, Frederich R, Maldonado M, Liu J, Pong A, Liu CC, Cannon CP; VERTIS CV Investigators. The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV. Diabetes Obes Metab. 2022 Jun;24(6):1114-1122. doi: 10.1111/dom.14677. Epub 2022 Mar 28. PubMed 35233908 ↗
  • Dagogo-Jack S, Pratley RE, Cherney DZI, McGuire DK, Cosentino F, Shih WJ, Liu J, Frederich R, Mancuso JP, Raji A, Gantz I. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Res Care. 2021 Oct;9(1):e002484. doi: 10.1136/bmjdrc-2021-002484. PubMed 34620621 ↗
  • Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Frederich R, Maldonado M, Liu CC, Liu J, Pong A, Cannon CP; VERTIS CV Investigators. Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial. Clin J Am Soc Nephrol. 2021 Sep;16(9):1345-1354. doi: 10.2215/CJN.01130121. Epub 2021 Jun 18. PubMed 34497110 ↗
  • Lingvay I, Greenberg M, Gallo S, Shi H, Liu J, Gantz I. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy. Diabetes Obes Metab. 2021 Jul;23(7):1640-1651. doi: 10.1111/dom.14385. Epub 2021 May 5. PubMed 33769675 ↗
  • Budoff MJ, Davis TME, Palmer AG, Frederich R, Lawrence DE, Liu J, Gantz I, Derosa G. Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV. Diabetes Ther. 2021 May;12(5):1279-1297. doi: 10.1007/s13300-021-01033-x. Epub 2021 Mar 15. PubMed 33721213 ↗
  • Strojek K, Pandey AS, Dell V, Sisson M, Wang S, Huyck S, Liu J, Gantz I. Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV. Diabetes Ther. 2021 Apr;12(4):1175-1192. doi: 10.1007/s13300-021-01018-w. Epub 2021 Mar 10. PubMed 33694093 ↗
  • Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Shih WJ, Frederich R, Maldonado M, Pong A, Cannon CP; VERTIS CV Investigators. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021 Jun;64(6):1256-1267. doi: 10.1007/s00125-021-05407-5. Epub 2021 Mar 4. PubMed 33665685 ↗
  • Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK; VERTIS CV Investigators. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020 Dec 8;142(23):2205-2215. doi: 10.1161/CIRCULATIONAHA.120.050255. Epub 2020 Oct 7. PubMed 33026243 ↗
  • Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. PubMed 32966714 ↗
  • Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Am J Manag Care. 2018 Apr;24(8 Suppl):S138-S145. PubMed 29693360 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Dec 2019, 73 months.

Results were first posted in Feb 2021, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 73 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2013
First posted
Nov 19, 2013
StartActual
Nov 4, 2013
Primary completionActual
Dec 27, 2019
CompletionActual
Dec 27, 2019
Results first posted
Feb 15, 2021
Last update
Sep 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01986881
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Nov 19, 2013
Start date
Nov 4, 2013
Primary completion
Dec 27, 2019
Completion
Dec 27, 2019
Results posted
Feb 15, 2021
Last update
Sep 23, 2022

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion